Mutations and prognosis in primary myelofibrosis
2013 · Leukemia · 739 citations
https://doi.org/10.1038/leu.2013.119
A
Animesh Pardanani
Mayo Clinic(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
803
Papers
40.1K
Citations
102
h-index
429
i10-index
Animesh Pardanani is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Myeloproliferative Neoplasms: Diagnosis and Treatment & Acute Myeloid Leukemia Research & Chronic Myeloid Leukemia Treatments. The author has an h-index of 102, co-authored 683 publications.
ORCID: 0000-0002-9084-4148Papers by this author
worksSafety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
2015 · JAMA Oncology · 453 citations
https://doi.org/10.1001/jamaoncol.2015.1590
MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
2018 · Journal of Clinical Oncology · 363 citations
https://doi.org/10.1200/jco.2018.78.9867
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
2018 · Leukemia · 288 citations
https://doi.org/10.1038/s41375-018-0107-z
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
2011 · Mayo Clinic Proceedings · 216 citations
https://doi.org/10.4065/mcp.2011.0518
Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
2020 · British Journal of Haematology · 216 citations
https://doi.org/10.1111/bjh.16380
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat